Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing therapies for neuroinflammatory diseases, has announced the granting of inducement awards to seven new non-executive employees. These equity awards were approved on October 10, 2024, in compliance with Nasdaq Listing Rule 5635(c)(4).
The awards consist of options to purchase a total of 643,500 shares of Annexon common stock. The options have a ten-year term and an exercise price of $7.45 per share, which was the closing price of Annexon's stock on October 15, 2024. The options will vest over 4 years, with 25% vesting on the first anniversary of the grant date and an additional 1/48th vesting monthly thereafter, subject to continued employment.
Annexon, Inc. (Nasdaq: ANNX), un'azienda biofarmaceutica focalizzata nello sviluppo di terapie per malattie neuroinfiammatorie, ha annunciato l'assegnazione di premi di induzione a sette nuovi dipendenti non esecutivi. Questi premi azionari sono stati approvati il 10 ottobre 2024, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
I premi consistono in opzioni per l'acquisto di un totale di 643.500 azioni ordinarie di Annexon. Le opzioni hanno una durata di dieci anni e un prezzo di esercizio di $7,45 per azione, che corrisponde al prezzo di chiusura delle azioni Annexon del 15 ottobre 2024. Le opzioni matureranno in 4 anni, con il 25% che matura al primo anniversario della data di concessione e un ulteriore 1/48 che matura mensilmente successivamente, soggetto a un'occupazione continuativa.
Annexon, Inc. (Nasdaq: ANNX), una empresa biofarmacéutica centrada en el desarrollo de terapias para enfermedades neuroinflamatorias, ha anunciado la concesión de premios de inducción a siete nuevos empleados no ejecutivos. Estos premios de capital fueron aprobados el 10 de octubre de 2024, de acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq.
Los premios consisten en opciones para comprar un total de 643,500 acciones comunes de Annexon. Las opciones tienen un plazo de diez años y un precio de ejercicio de $7.45 por acción, que fue el precio de cierre de las acciones de Annexon el 15 de octubre de 2024. Las opciones se adquirirán en un período de 4 años, con el 25% adquiriéndose en el primer aniversario de la fecha de concesión y un adicional de 1/48 que se adquirirá mensualmente después, sujeto a empleo continuo.
Annexon, Inc. (Nasdaq: ANNX), 신경 염증성 질환 치료제 개발에 주력하는 생명공학 회사가 7명의 신입 비상근 직원을 위한 유도 보상을 모집했다고 발표했습니다. 이 자본 보상은 2024년 10월 10일, 나스닥 상장 규칙 5635(c)(4)에 따라 승인되었습니다.
이 보상은 Annexon 일반 주식 643,500주를 구매할 수 있는 옵션으로 구성됩니다. 옵션의 유효 기간은 10년이며, 해당 주당 가격은 $7.45입니다. 이는 2024년 10월 15일 Annexon 주식의 종가입니다. 옵션은 4년 동안 분할 소유됩니다, 최초 부여일의 1주년에서 25%가 소유되고, 그 이후 매달 1/48씩 추가로 소유됩니다. 단, 지속적인 고용이 조건입니다.
Annexon, Inc. (Nasdaq: ANNX), une entreprise biopharmaceutique axée sur le développement de thérapies pour les maladies neuro-inflammatoires, a annoncé l'attribution de primes d'incitation à sept nouveaux employés non exécutifs. Ces primes en actions ont été approuvées le 10 octobre 2024, conformément à la règle de cotation 5635(c)(4) de Nasdaq.
Les primes consistent en des options d'achat d'un total de 643 500 actions ordinaires d'Annexon. Les options ont une durée de dix ans et un prix d'exercice de 7,45 $ par action, qui correspond au prix de clôture des actions d'Annexon au 15 octobre 2024. Les options s'acquitteront sur 4 ans, avec 25 % s'acquittant à la première anniversaire de la date d'attribution et un supplément de 1/48 s'acquittant chaque mois par la suite, sous réserve d'un emploi continu.
Annexon, Inc. (Nasdaq: ANNX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für neuroinflammatorische Erkrankungen konzentriert, hat die Vergabe von Anreizprämien an sieben neue nicht-executive Mitarbeiter bekannt gegeben. Diese Kapitalprämien wurden am 10. Oktober 2024 genehmigt, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4).
Die Prämien bestehen aus Optionen zum Kauf von insgesamt 643.500 Aktien von Annexon. Die Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 7,45 $ pro Aktie, was dem Schlusskurs der Annexon-Aktien am 15. Oktober 2024 entspricht. Die Optionen werden über 4 Jahre vesten, wobei 25 % am ersten Jahrestag des Gewährungsdatums und monatlich danach zusätzlich 1/48 vesten, vorbehaltlich einer fortgesetzten Beschäftigung.
- Annexon granted stock options to attract and retain new non-executive employees
- The company issued a significant number of stock options (643,500 shares) as part of its employee incentive program
- The issuance of new stock options may lead to potential dilution for existing shareholders
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 643,500 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule in the part of the immune system that protects against infection. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – neurodegenerative, ophthalmic and autoimmune diseases – and includes investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver potentially game-changing therapies to patients so that they can live their best lives. When they thrive, we thrive. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
How many new employees received inducement grants from Annexon (ANNX)?
What is the exercise price of the stock options granted by Annexon (ANNX) on October 15, 2024?
What is the vesting schedule for the stock options granted by Annexon (ANNX)?
How many shares of Annexon (ANNX) common stock are covered by the inducement grants?
